Royal Biologics, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $693,368 | 494 | 43.6% |
| Royalty or License | $534,242 | 136 | 33.6% |
| Unspecified | $186,782 | 42 | 11.8% |
| Food and Beverage | $112,836 | 1,566 | 7.1% |
| Travel and Lodging | $36,279 | 36 | 2.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $16,800 | 10 | 1.1% |
| Long term medical supply or device loan | $4,624 | 1 | 0.3% |
| Honoraria | $3,500 | 7 | 0.2% |
| Entertainment | $926.09 | 8 | 0.1% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| Platelet Rich Fibrin Matrix in ACDF Surgery: Is it an effective bone grafting option used alone? | $50,929 | 0 | 4 |
| : Single Center Prospective Registry to Evaluate Use and Outcomes of Royal Biologics Products in Spinal Fusion Surgery | $39,000 | 1 | 6 |
| Single Center Prospective Registry to Evaluate Use and Outcomes of Royal Biologics Products in Spinal | $27,750 | 1 | 2 |
| A Randomized Controlled Multicenter Trial, Examining the Effect of Derm-Maxx on the Healing Rate of Chronic Diabetic Foot Ulcers | $25,850 | 1 | 9 |
| A PILOT STUDY TO EVALUATE THE EFFICACY OF NON-DIMETHYL SULFOXIDE (NON-DMSO) VIABLE UMBILICAL CORD GRAFT ONDIABETIC FOOT ULCERS | $21,420 | 2 | 2 |
| Single Center Prospective Registry to Evaluate Use and Outcomes of Royal Biologics Products in Spinal Fusion Surgery | $10,250 | 1 | 3 |
| Foot & Ankle Fusion Case Series | $7,250 | 1 | 4 |
| PILOT STUDY TO EVALUATE THE EFFECTS OF PLATELET RICH FIBRIN MATRIX (FIBRINET) ON DIABETIC FOOT ULCERS | $3,085 | 0 | 1 |
| PILOT STUDY TO EVALUATE THE EFFECTS OF PLATELET RICH FIBRIN MATRIX FIBRINET ON DIABETIC FOOT ULCERS | $1,248 | 1 | 1 |
Payments by Medical Specialty
Top Paid Doctors — Page 22
| Doctor | Specialty | Location | Total | 2021 |
|---|---|---|---|---|
| Mr. Michael Kayal, Rpa-C, RPA-C | Surgical | Franklin Lakes, NJ | $10.40 | $0 |
| James Verardi, Pa-C, PA-C | Physician Assistant | Franklin Lakes, NJ | $10.40 | $0 |
| Robert Villa, Pa-C, PA-C | Physician Assistant | Franklin Lakes, NJ | $10.40 | $0 |
| Dr. Alan Zalkowitz, M.d, M.D | Rheumatology | Franklin Lakes, NJ | $10.40 | $0 |
| Michael Booth, Pa, PA | Physician Assistant | Franklin Lakes, NJ | $10.40 | $0 |
| Erin Unger, Pa-C, PA-C | Physician Assistant | Franklin Lakes, NJ | $10.40 | $0 |
| Dr. Jason Galante, D.p.m, D.P.M | Foot & Ankle Surgery | Springfield, NJ | $10.24 | $0 |
Top Products
- Fibrinet $332,356
- AmnioMaxx $30,401
Associated Products (8)
Payment Categories
- Food & Beverage $112,836
- Consulting $693,368
- Travel & Lodging $36,279
- Research $186,782
- Royalties $534,242
About Royal Biologics, Inc.
Royal Biologics, Inc. has made $1.6M in payments to 541 healthcare providers, recorded across 2,300 transactions in the CMS Open Payments database. In 2024, the company paid $492,326. The top product by payment volume is Fibrinet ($332,356).
Payments were distributed across 56 medical specialties. The top specialty by payment amount is Orthopaedic Surgery of the Spine ($441,678 to 33 doctors).
Payment categories include: Food & Beverage ($112,836), Consulting ($693,368), Research ($186,782), Travel & Lodging ($36,279), Royalties ($534,242).
Royal Biologics, Inc. is associated with 8 products in the CMS Open Payments database, including Fibrinet, AmnioMaxx, and MaxxCell.